<DOC>
	<DOCNO>NCT01034657</DOCNO>
	<brief_summary>This study assess efficacy safety LBH589 single agent combination ESA red blood cell transfusion-dependent Low Int-1 MDS patient either refractory ESA low probability response . The study non-randomized core phase follow randomized phase .</brief_summary>
	<brief_title>LBH589 Alone Combination With Erythropoietin Stimulating Agents ( ESA ) Patients With Low Int-1 Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Key Patients low risk MDS ( LOW INT1 accord IPSS ) Red blood cell transfusion dependency least 4 Units/8 week . Not respond Erythropoietin stimulate agent ( ESA ) low chance Ageadjusted normal cardiac , kidney , liver function Key Concomitant use ESA Concomitant use investigational drug Other malignancy remission least 1 year Platelet Count &lt; 75 x 109/L Impaired cardiac function clinically significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>bone marrow</keyword>
	<keyword>anemia</keyword>
	<keyword>cytopenia</keyword>
	<keyword>transfusion dependance</keyword>
	<keyword>EPO</keyword>
	<keyword>ESA</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>LBH589</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>hematopoietic improvement</keyword>
	<keyword>IPSS Low</keyword>
	<keyword>IPSS Int-1</keyword>
	<keyword>HI-E</keyword>
	<keyword>HDAC Inhibitor</keyword>
	<keyword>HDAC-I</keyword>
	<keyword>DAC-I</keyword>
	<keyword>Deacetylase-Inhibitor</keyword>
	<keyword>Histone Deacetylase-Inhibitor</keyword>
	<keyword>red blood cell transfusion</keyword>
</DOC>